<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2007-7459</journal-id>
<journal-title><![CDATA[Horizonte sanitario]]></journal-title>
<abbrev-journal-title><![CDATA[Horiz. sanitario]]></abbrev-journal-title>
<issn>2007-7459</issn>
<publisher>
<publisher-name><![CDATA[Universidad Juárez Autónoma de Tabasco, División Académica de Ciencias de la Salud]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2007-74592022000300433</article-id>
<article-id pub-id-type="doi">10.19136/hs.a21n3.4769</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Costo-efectividad del tratamiento con insulina para el control de diabetes mellitus tipo 2 en México]]></article-title>
<article-title xml:lang="en"><![CDATA[Cost-effectiveness in insulin treatment for type 2 diabetes mellitus control in Mexico]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López-Esteves]]></surname>
<given-names><![CDATA[Pablo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rangel-Osuna]]></surname>
<given-names><![CDATA[Felipe]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Yañez-Santaolalla]]></surname>
<given-names><![CDATA[Jair]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández-Castro]]></surname>
<given-names><![CDATA[Amairani]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Arredondo-López&#8224;]]></surname>
<given-names><![CDATA[Armando]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Salud Pública. México  ]]></institution>
<addr-line><![CDATA[ Morelos]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Nacional de Salud Pública. México  ]]></institution>
<addr-line><![CDATA[ Morelos]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Nacional de Salud Pública. México  ]]></institution>
<addr-line><![CDATA[ Morelos]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Instituto Nacional de Salud Pública. México  ]]></institution>
<addr-line><![CDATA[ Morelos]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Instituto Nacional de Salud Pública. México  ]]></institution>
<addr-line><![CDATA[ Morelos]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2022</year>
</pub-date>
<volume>21</volume>
<numero>3</numero>
<fpage>433</fpage>
<lpage>441</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2007-74592022000300433&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2007-74592022000300433&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2007-74592022000300433&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: Identificar la intervención más costo-efectiva para el tratamiento de la diabetes mellitus tipo 2, en el primer nivel de atención, cuando el paciente requiere del uso de algún tipo de insulina, con base en estudios clínicos previos.  Material y métodos: Se efectuó un análisis costo-efectividad desde la perspectiva del proveedor. Se obtuvieron los costos de tres tipos de insulina como fármaco de control: insulina glargina, insulina protamina neutra de Hagedorn (NPH) e insulina lispro/lispro protamina 25-75 UI. Los indicadores de efectividad se obtuvieron de estudios previos que analizaron el efecto de los fármacos sobre la hemoglobina glucosilada (HbA1c).  Resultados: La intervención que presentó el mejor coeficiente costo- efectividad fue el tratamiento con insulina glargina, con un valor de 570, comparado con 643.1 de la insulina NPH y 572.6 de la insulina lispro/lispro protamina 25-75 UI.  Conclusiones: La insulina glargina es el tratamiento en pacientes que requieren insulinas y no presentan daño microvascular, la que presenta la mejor evidencia para invertir debido a su costo y su efectividad (analizados a través del coeficiente costo-efectividad). Estos resultados pueden considerarse en el contexto mexicano para mejorar la adquisición de medicamentos y los estándares de tratamiento para pacientes con diabetes mellitus tipo 2.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective: To identify the best cost-effective intervention for the treatment of type 2 diabetes mellitus, at the first level of care, when the patient requires the use of insulin, based on previous clinical analysis.  Materials and methods: A cost-effectiveness analysis was carried out, from the provider perspective. The cost of three types of insulin as a control drug were obtained: glargine insulin, neutral protamine Hagedorn (NPH) insulin and lispro insulin/lispro protamine 25-75 IU. The effectiveness indicators were obtained from previous studies that analyzed the effect on glycated hemoglobin (HbA1c).  Results: The intervention that presented the best cost-effective coefficient was the treatment with glargine insulin, with a value of 570, compared to 643.1 for the NPH insulin and 57 for the lispro/lispro protamine insulin.  Conclusions: Glargine insulin is the treatment in patients who require insulins, without microvascular damage, that presents the best evidence to invest in, because of its cost and efficiency (analyzed through a cost- efficiency coefficient). These results may be considered in the Mexican context to improve drug&#8217;s acquisition and the treatment standards to treat type 2 diabetes mellitus.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Diabetes tipo 2]]></kwd>
<kwd lng="es"><![CDATA[Costo-efectividad]]></kwd>
<kwd lng="es"><![CDATA[Insulina]]></kwd>
<kwd lng="en"><![CDATA[Type 2 diabetes]]></kwd>
<kwd lng="en"><![CDATA[Cost-effectiveness]]></kwd>
<kwd lng="en"><![CDATA[Insulin]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[DeFronzo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrannini]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insulin Resistance:AMultifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>1991</year>
<volume>14</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>173-94</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<collab>Global Burden of Disease Study</collab>
<source><![CDATA[Results]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Seattle, United States ]]></publisher-loc>
<publisher-name><![CDATA[Institute for Health Metrics and Evaluation]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<source><![CDATA[Características de las Defunciones Registradas en México durante el 2020, Preliminar. Comunicado de prensa 402/21]]></source>
<year>2021</year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[INEGI]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shamah-Levy]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Romero-Martínez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Barrientos-Gutiérrez]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Cuevas-Nasu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bautista-Arredondo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Colchero]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[GaonaPineda]]></surname>
<given-names><![CDATA[EB]]></given-names>
</name>
<name>
<surname><![CDATA[Lazcano-Ponce]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Barnetche]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Alpuche-Arana]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rivera-Dommarco]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Encuesta Nacional de Salud y Nutrición 2020 sobre Covid-19. Resultados nacionales]]></source>
<year>2021</year>
<publisher-loc><![CDATA[Cuernavaca, México ]]></publisher-loc>
<publisher-name><![CDATA[Instituto Nacional de Salud Pública]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<collab>Secretaría de Salud</collab>
<source><![CDATA[Programa de Acción Específico para la Prevención y Control de la Diabetes Mellitus 2013-2018]]></source>
<year></year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[SSA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<collab>American Diabetes Association</collab>
<article-title xml:lang=""><![CDATA[Standards of Medical Care in Diabetes 2019]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2019</year>
<volume>42</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<collab>Instituto Mexicano del Seguro Social</collab>
<source><![CDATA[Diagnóstico y Tratamiento Farmacológico de la Diabetes Mellitus Tipo 2 en el Primer Nivel de Atención. Guía de Evidencias y Recomendaciones: Guía de Práctica Clínica]]></source>
<year>2018</year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hanefeld]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of insulin in type 2 diabetes: what we learned from recent clinical trials on the benefits of early insulin initiation]]></article-title>
<source><![CDATA[Diabetes Metab]]></source>
<year>2014</year>
<volume>40</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>391-9</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<collab>American Diabetes Association</collab>
<article-title xml:lang=""><![CDATA[Summary of Revisions: Standards of Medical Care in Diabetes-2021]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2021</year>
<volume>44</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>S4-6</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="">
<collab>Portal de compras del IMSS</collab>
<source><![CDATA[]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Retnakaran]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Emery]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Ye]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[SB.]]></given-names>
</name>
<name>
<surname><![CDATA[Reichert]]></surname>
<given-names><![CDATA[SM.]]></given-names>
</name>
<name>
<surname><![CDATA[McInnes]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Short-term intensive insulin as induction and maintenance therapy for the preservation of beta-cell function in early type 2 diabetes (RESET-IT Main): A 2-year randomized controlled trial]]></article-title>
<source><![CDATA[Diabetes Obes Metab.]]></source>
<year>2021</year>
<volume>23</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1926-35</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mata-Cases]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tipos de insulina]]></article-title>
<source><![CDATA[Diabetes Práctica]]></source>
<year>2017</year>
<volume>08</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1-24</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="">
<source><![CDATA[Calculadora de inflación]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="">
<collab>Instituto Mexicano del Seguro Social</collab>
<source><![CDATA[Adquiridos en la Compra Consolidada 2017-2018]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="">
<collab>Portal de compras del IMSS</collab>
<source><![CDATA[]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="">
<collab>Diario Oficial de la Federación</collab>
<source><![CDATA[. Acuerdo para la Aprobación de los Costos Unitarios por Nivel de Atención Médica actualizados al año 2020]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="">
<collab>Secretaría de Hacienda y Crédito Público</collab>
<source><![CDATA[Catálogo de puestos y tabuladores de sueldos y salarios para personal de las ramas médica, y grupos afines. Subsecretaría de Egresos]]></source>
<year>2020</year>
<page-range>11</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Swinnen]]></surname>
<given-names><![CDATA[SG.]]></given-names>
</name>
<name>
<surname><![CDATA[Simon]]></surname>
<given-names><![CDATA[ACR.]]></given-names>
</name>
<name>
<surname><![CDATA[Holleman]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Hoekstra]]></surname>
<given-names><![CDATA[JB.]]></given-names>
</name>
<name>
<surname><![CDATA[DeVries]]></surname>
<given-names><![CDATA[JH.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insulin detemir versus insulin glargine for type 2 diabetes mellitus]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2011</year>
<volume>2011</volume>
<numero>7</numero>
<issue>7</issue>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pollom]]></surname>
<given-names><![CDATA[RK.]]></given-names>
</name>
<name>
<surname><![CDATA[Ilag]]></surname>
<given-names><![CDATA[LL.]]></given-names>
</name>
<name>
<surname><![CDATA[Lacaya]]></surname>
<given-names><![CDATA[LB.]]></given-names>
</name>
<name>
<surname><![CDATA[Morwick]]></surname>
<given-names><![CDATA[TM.]]></given-names>
</name>
<name>
<surname><![CDATA[Ortiz Carrasquillo]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lilly Insulin Glargine Versus Lantus ® in Insulin-Naïve and Insulin-Treated Adults with Type 2 Diabetes: A Randomized, Controlled Trial (ELEMENT 5)]]></article-title>
<source><![CDATA[Diabetes Ther]]></source>
<year>2019</year>
<volume>10</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>189-203</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gross]]></surname>
<given-names><![CDATA[JL.]]></given-names>
</name>
<name>
<surname><![CDATA[Rojas]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Tinahones]]></surname>
<given-names><![CDATA[FJ.]]></given-names>
</name>
<name>
<surname><![CDATA[Cleall]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of a premixed versus a basal- plus insulin regimen as intensification for type 2 diabetes by timing of the main meal]]></article-title>
<source><![CDATA[Curr Med Res Opin]]></source>
<year>2016</year>
<volume>32</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1109-16</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jimenes-Manzorro]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[INSULINA LISPRO, LISPRO PROTAMINA (NPL), LISPRO + NPL Informe para la Comisión de Farmacia y Terapéutica]]></article-title>
<source><![CDATA[Hospital General Universitario Gregorio Marañón]]></source>
<year>2007</year>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Semlitsch]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Engler]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Siebenhofer]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Jeitler]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Berghold]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Horvath]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2020</year>
<volume>11</volume>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="book">
<collab>Eisenberg Center at Oregon Health &amp; Science University</collab>
<source><![CDATA[Insulina premezclada para la diabetes tipo 2: Guía para adultos. 2010. Las Guías Sumarias de los Consumidores]]></source>
<year>2006</year>
<publisher-loc><![CDATA[US ]]></publisher-loc>
<publisher-name><![CDATA[Rockville (MD): Agency for Healthcare Research and Quality]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cameron]]></surname>
<given-names><![CDATA[CG.]]></given-names>
</name>
<name>
<surname><![CDATA[Bennett]]></surname>
<given-names><![CDATA[HA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-effectiveness of insulin analogues for diabetes mellitus]]></article-title>
<source><![CDATA[CMAJ]]></source>
<year>2009</year>
<volume>180</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>400-7</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pollock]]></surname>
<given-names><![CDATA[R.F.]]></given-names>
</name>
<name>
<surname><![CDATA[Curtis]]></surname>
<given-names><![CDATA[B.H.]]></given-names>
</name>
<name>
<surname><![CDATA[Smith-Palmer]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A UK Analysis of the Cost-Effectiveness of Humalog Mix75/25 and Mix50/50 Versus Long-Acting Basal Insulin]]></article-title>
<source><![CDATA[Adv Therapy]]></source>
<year>2012</year>
<volume>29</volume>
<page-range>1051-66</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Villarreal-Ríos]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Montoya-Hernández]]></surname>
<given-names><![CDATA[MA.]]></given-names>
</name>
<name>
<surname><![CDATA[Vargas-Daza]]></surname>
<given-names><![CDATA[ER.]]></given-names>
</name>
<name>
<surname><![CDATA[Cervantes-Becerra]]></surname>
<given-names><![CDATA[RG.]]></given-names>
</name>
<name>
<surname><![CDATA[Galicia-Rodríguez]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez- González]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Costo efectividad de insulina lispro protamina (NPL) vs. combinación de insulina NPH + insulina rápida]]></article-title>
<source><![CDATA[Rev. OFIL·ILAPHAR]]></source>
<year>2020</year>
<volume>30</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>221-6</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
